Refine
Year of publication
Document Type
- Article (90) (remove)
Has Fulltext
- yes (90)
Is part of the Bibliography
- no (90)
Keywords
- ADHD (17)
- Depression (9)
- Bipolar disorder (7)
- Genetics (6)
- bipolar disorder (5)
- Human behaviour (4)
- Psychiatric disorders (4)
- Suicide (4)
- Dopamine (3)
- Neuroscience (3)
- Physical activity (3)
- Treatment (3)
- continuous performance test (3)
- fMRI (3)
- schizophrenia (3)
- Attention-deficit/hyperactivity disorder (2)
- Biomarker (2)
- Brain (2)
- COVID-19 (2)
- Clinical genetics (2)
- Comorbidity (2)
- Diagnostic markers (2)
- Emotion regulation (2)
- Exercise (2)
- Inflammation (2)
- L-DOPA (2)
- MDD (2)
- Major depressive disorder (2)
- PARK2 (2)
- Pandemic (2)
- Predominant polarity (2)
- Primary care (2)
- attention (2)
- biomarker (2)
- depression (2)
- hyperactivity (2)
- impulsivity (2)
- machine learning (2)
- polygenic risk score (2)
- 14-3-3 gene family (1)
- A2BP1 (1)
- ADHD differential diagnosis (1)
- AKI (1)
- AMPA (1)
- Accidents (1)
- Acidification (1)
- Adjuvant procedure (1)
- Adjuvantes Verfahren (1)
- Adult-onset ADHD (1)
- Affect (1)
- Affective disorders (1)
- Agoraphobia (1)
- Ambulatory Assessment (1)
- Amino acids (1)
- Amisulpride (1)
- Amphetamine (1)
- Amygdala (1)
- Animal models (1)
- Antidepressant (1)
- Anxiolytic pharmacological therapy (1)
- Atomoxetine (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention deficit (1)
- Attention-deficit / hyperactivity disorder (1)
- Attentional bias (1)
- Batten disease (1)
- Behavioral tests (1)
- Big Five (1)
- Brain DNA methylation (1)
- Bright light therapy (1)
- Brms (1)
- Brodalumab (1)
- CAPON (1)
- CDH13 (1)
- CNVs (1)
- COMT (1)
- Cardiac surgery (1)
- Central Europe (1)
- Circadian (1)
- Cln3 (1)
- Co-morbidity (1)
- Cognitive (1)
- Cognitive dysfunction (1)
- Cognitive enhancers of exposure therapy (1)
- Cognitive impairment (1)
- Comorbidities (1)
- Completed suicide (1)
- Consensus (1)
- Copy number (1)
- Course (1)
- DTI (1)
- DYT1 (1)
- Developmental programming (1)
- Developmental trajectory (1)
- Diagnosis (1)
- Diagnostic medicine (1)
- Diagnostic test (1)
- Dietary intake (1)
- Differential diagnosis (1)
- Dot-probe task (1)
- EBM (1)
- Early (prenatal and postnatal) life experiences (1)
- Ecological Momentary Assessment (EMA) (1)
- Ecological momentary assessment (1)
- Energy (1)
- Environmental enrichment (1)
- Epigenetics (1)
- Euthymic phase (1)
- Evidence-based (1)
- Evidence-based drug discovery (1)
- Evidenzbasierung (1)
- Explicit (1)
- Fruit fly (1)
- GHQ-28 (1)
- GWAS (1)
- Gaba (1)
- Gene (1)
- Genetic syndromes (1)
- Glutamate (1)
- Guidelines (1)
- Healthy Living Index (HLI) (1)
- Hippocampus (1)
- Hyperactivity (1)
- IL-17 (1)
- Imaging genetics (1)
- Immunity (1)
- Immunogenetics (1)
- Immunology (1)
- Implicit (1)
- Injuries (1)
- Intervention (1)
- KDIGO (1)
- Konsens (1)
- LFP (1)
- Lafora disease (1)
- Langzeiteffekt (1)
- Learning and memory (1)
- Leitlinien (1)
- Lithium (1)
- Long-term effect (1)
- Longitudinal (1)
- MVPA (1)
- Maintenance treatment (1)
- Mania (1)
- Maternal separation (1)
- Mechanism of action (1)
- Memory (1)
- Mental disorder (1)
- Mental health and psychiatry (1)
- Mental health disorders (1)
- Metabolic diseases (1)
- Methylphenidate (1)
- Mitochondrial dysfunction (1)
- Molecular neuroscience (1)
- Monetary incentive delay (1)
- Monitoring (1)
- Mood (1)
- Mouse (1)
- Multilevel two-part modelling (1)
- Multiplex immunoassay (1)
- NMDA (1)
- NOS-I (1)
- NOS1AP (1)
- NPSR1 (1)
- Nesplora Aquarium (1)
- Neurodevelopmental disorder (1)
- Neuromodulatorisches Netzwerk (1)
- Neuromodulatory network (1)
- Neurostimulation (1)
- Norepinephrine (1)
- Obesity (1)
- Outcome (1)
- Panic disorder (1)
- Patients (1)
- Personalized medicine (1)
- Phenylketonuria (PKU) (1)
- Physical fitness (1)
- Physical self-perception (1)
- Physicians (1)
- Polarity index (1)
- Polygenic risk score (1)
- Postvention (1)
- Prediction (1)
- Predictive markers (1)
- Psychedelics (1)
- Psychiatric traits (1)
- Psychiatry (1)
- Qb-Test (1)
- QbTest® (1)
- Quality of life (1)
- R (1)
- RBFOX1 (1)
- RDoC (1)
- RNAi (1)
- Randomized controlled trial (1)
- Rapid acting antidepressant (1)
- Research article (1)
- Reward (1)
- Rodents (1)
- SARS-CoV2 (1)
- SUD (1)
- Schizophrenia (1)
- Scientific community (1)
- Seasonal variation (1)
- Self-efficacy (1)
- Self-esteem (1)
- Semicontinuous (1)
- Solar insolation (1)
- Stimulant (1)
- Stress resilience (1)
- Stress vulnerability/resilience genes (1)
- Striatum (1)
- Suicidal behavior (1)
- Suicidal thoughts (1)
- Suicidality (1)
- Suicide attempt (1)
- Suizidalität (1)
- Sunlight (1)
- Synaptic dysfunction (1)
- TBSS (1)
- TOR1A (1)
- Trajectories (1)
- Two-hit hypothesis (1)
- Tyrosinemia (1)
- UPPS (1)
- Westphal-Paradigm (1)
- Wirkmechanismus (1)
- Working memory capacity (1)
- YWHAE (1)
- YWHAZ (1)
- Yoga (1)
- Zebrafish (1)
- accidents (1)
- adaptation (1)
- adeno-associated virus (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adversity (1)
- affective disorder (1)
- affective disorders (1)
- aggressiveness (1)
- aging (1)
- agreeableness (1)
- alcohol use disorder (1)
- alcohol use disorder (AUD) (1)
- allostasis (1)
- amisulpride (1)
- associative memory (1)
- attention deficit hyperactivity disorder (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attention-deficit/hyperactivity disorder (1)
- autism (1)
- bipolar disorders (1)
- blood (1)
- body mass index (1)
- ceramides (1)
- children (1)
- cognition (1)
- common variant (1)
- common variants (1)
- comorbidity (1)
- coping (1)
- cross-sectional study (1)
- data science (1)
- dementia (1)
- development (1)
- diabetes mellitus (1)
- diet (1)
- dietary assessment (1)
- disease modelling (1)
- disease prevalence (1)
- dopamine (1)
- dynamic system (1)
- early recognition (1)
- ecological momentary assessment (1)
- endocannabinoids (1)
- epigenetics (1)
- epilepsy (1)
- euthymic (1)
- eutrophication (1)
- ex-Gaussian analysis (1)
- executive functions (1)
- expression studies (1)
- extraversion (1)
- face-name association task (1)
- fear conditioning (1)
- fear generalization (1)
- feasibility (1)
- forest ecology (1)
- functional connectivity (1)
- gender (1)
- genetic phenotypes (1)
- genetic variants (1)
- genetics (1)
- gene×environment interactions (1)
- glucose metabolism (1)
- graph theory (1)
- hiPSC (1)
- homeostasis (1)
- inflammation (1)
- insula (1)
- insulin resistance (1)
- juvenile myoclonic epilepsy (1)
- lifestyle (1)
- lipids (1)
- mHealth (1)
- machine learning (ML) (1)
- major depression (1)
- major depression (MD) (1)
- major depressive disorder (1)
- major depressive disorder (MDD) (1)
- maturation (1)
- mental health (1)
- metabolic syndrome (1)
- microtemporal processes (1)
- mind wandering (1)
- mitochondria (1)
- mobile phone (1)
- morphometry (1)
- motor activity (MA) (1)
- nNOS (1)
- naturalistic sample (1)
- neurodevelopment (1)
- neurodevelopmental disorders (1)
- neuropsychology (1)
- neuroticism (1)
- nitric oxide (1)
- obesity (1)
- pharmaco-fMRI (1)
- pharmacogenetics (1)
- pharmacoresistance (1)
- physical activity (1)
- prediabetes (1)
- progressive myoclonus epilepsy (1)
- proteome (1)
- psychiatric disorders (1)
- psychosocial stress (1)
- quality of life (1)
- rare mendelian disorders (1)
- rare variant (1)
- rare variants (1)
- resting-state fMRI (1)
- resting‐state (1)
- risk genes (1)
- schizophrenia spectrum (1)
- single subject classification (1)
- skin conductance (1)
- smartphone-app (1)
- stress (1)
- substance abuse disorder (1)
- tandem mass spectrometry (1)
- temporal classification (1)
- transcriptomics (1)
- usability (1)
- validity (1)
- ventral tegmental area (1)
- venturesomeness (1)
- viral gene transfer (1)
- white-matter (1)
- within-person factors (1)
- working memory (1)
Institute
- Medizin (86)
- Psychologie (6)
- Psychologie und Sportwissenschaften (3)
- Biowissenschaften (1)
- Präsidium (1)
Multiple Sklerose (MS) ist die häufigste entzündliche Erkrankung des zentralen Nervensystems (ZNS) im jungen Erwachsenenalter. Weltweit sind mehr als 2,3 Mio. Menschen betroffen – Frauen doppelt so häufig wie Männer. Die Erkrankung ist gekennzeichnet durch eine autoimmunvermittelte Demyelinisierung im ZNS einhergehend mit motorischen, sensorischen und neuropsychiatrischen Defiziten.
Bereits Charcot beschrieb im 19. Jahrhundert auch psychiatrische Syndrome als Teil der Erkrankung. Am häufigsten treten Depressionen und Angststörungen auf [1]. Im Krankheitsverlauf können auch kognitive Defizite und organische Persönlichkeitsveränderungen hinzukommen [8]. Psychotische Symptome sind selten und spielen eher eine Rolle als Nebenwirkung der MS-Therapie mit Kortikosteroiden und seltener β‑Interferonen [5].
Bei unserer Patientin trat die akute psychotische Störung als erste klinische Manifestation der MS auf und führte zur Diagnosestellung.
Changes in glutamatergic neuroplasticity has been proposed as one of the core mechanisms underlying the pathophysiology of depression. In consequence components of the glutamatergic synapse have been explored as potential targets for antidepressant treatment. The rapid antidepressant effect of the NMDA receptor antagonist ketamine and subsequent approval of its S-enantiomer (i.e. esketamine), have set the precedent for investigation into other glutamatergic rapid acting antidepressants (RAADs). In this review, we discuss the potential of the different glutamatergic targets for antidepressant treatment. We describe important clinical outcomes of several key molecules targeting components of the glutamatergic synapse and their applicability as RAADs. Specifically, here we focus on substances beyond (es)ketamine, for which meaningful data from clinical trials are available, including arketamine, esmethadone, nitrous oxide and other glutamate receptor modulators. Molecules only successful in preclinical settings and case reports/series are only marginally discussed. With this review, we aim underscore the critical role of glutamatergic modulation in advancing antidepressant therapy, thereby possibly enhancing clinical outcomes but also to reducing the burden of depression through faster therapeutic effects.
Neurometabolic diseases (NMDs) are typically caused by genetic abnormalities affecting enzyme functions, which in turn interfere with normal development and activity of the nervous system. Although the individual disorders are rare, NMDs are collectively relatively common and often lead to lifelong difficulties and high societal costs. Neuropsychiatric manifestations, including ADHD symptoms, are prominent in many NMDs, also when the primary biochemical defect originates in cells and tissues outside the nervous system. ADHD symptoms have been described in phenylketonuria, tyrosinemias, alkaptonuria, succinic semialdehyde dehydrogenase deficiency, X-linked ichthyosis, maple syrup urine disease, and several mitochondrial disorders, but are probably present in many other NMDs and may pose diagnostic and therapeutic challenges. Here we review current literature linking NMDs with ADHD symptoms. We cite emerging evidence that many NMDs converge on common neurochemical mechanisms that interfere with monoamine neurotransmitter synthesis, transport, metabolism, or receptor functions, mechanisms that are also considered central in ADHD pathophysiology and treatment. Finally, we discuss the therapeutic implications of these findings and propose a path forward to increase our understanding of these relationships.
Studies have demonstrated an increased risk of accidents and injuries in children, adolescents and adults with attention-deficit/hyperactivity disorder (ADHD). However, little is known about how accident risk may alter over the lifespan. Additionally, it would be important to know if the most common types of accidents and injuries differ in ADHD patients over different age groups. Furthermore, there is increasing evidence of an ameliorating effect of ADHD medication on accident risk. Lastly, the underlying risk factors and causal mechanisms behind increased accident risk remain unclear. We therefore conducted a systematic review focusing on the above described research questions. Our results suggested that accident/injury type and overall risk changes in ADHD patients over the lifespan. ADHD medication appeared to be similarly effective at reducing accident risk in all age groups. However, studies with direct comparisons of accident/injuries and effects of medication at different age groups or in old age are still missing. Finally, comorbidities associated with ADHD such as substance abuse appear to further increase the accident/injury risk.
Introduction: Previous studies have established graph theoretical analysis of functional network connectivity (FNC) as a potential tool to detect neurobiological underpinnings of psychiatric disorders. Despite the promising outcomes in studies that examined FNC aberrancies in bipolar disorder (BD) and major depressive disorder (MDD), there is still a lack of research comparing both mood disorders, especially in a nondepressed state. In this study, we used graph theoretical network analysis to compare brain network properties of euthymic BD, euthymic MDD and healthy controls (HC) to evaluate whether these groups showed distinct features in FNC.
Methods: We collected resting‐state functional magnetic resonance imaging (fMRI) data from 20 BD patients, 15 patients with recurrent MDD as well as 30 age‐ and gender‐matched HC. Graph theoretical analyses were then applied to investigate functional brain networks on a global and regional network level.
Results: Global network analysis revealed a significantly higher mean global clustering coefficient in BD compared to HC. We further detected frontal, temporal and subcortical nodes in emotion regulation areas such as the limbic system and associated regions exhibiting significant differences in network integration and segregation in BD compared to MDD patients and HC. Participants with MDD and HC only differed in frontal and insular network centrality.
Conclusion: In conclusion, our findings indicate that a significantly altered brain network topology in the limbic system might be a trait marker specific to BD. Brain network analysis in these regions may therefore be used to differentiate euthymic BD not only from HC but also from patients with MDD.
New innovative neuropsychological tests in attention deficit hyperactivity disorder ADHD have been proposed as objective measures for diagnosis and therapy. The current study aims to investigate two different commercial continuous performance tests (CPT) in a head-to-head comparison regarding their comparability and their link with clinical parameters. The CPTs were evaluated in a clinical sample of 29 adult patients presenting in an ADHD outpatient clinic. Correlational analyses were performed between neuropsychological data, clinical rating scales, and a personality-based measure. Though inattention was found to positively correlate between the two tests (r = 0.49, p = 0.01), no association with clinical measures and inattention was found for both tests. While hyperactivity did not correlate between both tests, current ADHD symptoms were positively associated with Nesplora Aquarium’s motor activity (r = 0.52 to 0.61, p < 0.05) and the Qb-Test’s hyperactivity (r = 0.52 to 0.71, p < 0.05). Conclusively, the overall comparability of the tests was limited and correlation with clinical parameters was low. While our study shows some interesting correlation between clinical symptoms and sub-scales of these tests, usage in clinical practice is not recommended.
Pattern recognition approaches to the analysis of neuroimaging data have brought new applications such as the classification of patients and healthy controls within reach. In our view, the reliance on expensive neuroimaging techniques which are not well tolerated by many patient groups and the inability of most current biomarker algorithms to accommodate information about prior class frequencies (such as a disorder's prevalence in the general population) are key factors limiting practical application. To overcome both limitations, we propose a probabilistic pattern recognition approach based on cheap and easy-to-use multi-channel near-infrared spectroscopy (fNIRS) measurements. We show the validity of our method by applying it to data from healthy controls (n = 14) enabling differentiation between the conditions of a visual checkerboard task. Second, we show that high-accuracy single subject classification of patients with schizophrenia (n = 40) and healthy controls (n = 40) is possible based on temporal patterns of fNIRS data measured during a working memory task. For classification, we integrate spatial and temporal information at each channel to estimate overall classification accuracy. This yields an overall accuracy of 76% which is comparable to the highest ever achieved in biomarker-based classification of patients with schizophrenia. In summary, the proposed algorithm in combination with fNIRS measurements enables the analysis of sub-second, multivariate temporal patterns of BOLD responses and high-accuracy predictions based on low-cost, easy-to-use fNIRS patterns. In addition, our approach can easily compensate for variable class priors, which is highly advantageous in making predictions in a wide range of clinical neuroimaging applications. Hum Brain Mapp, 2013. © 2012 Wiley Periodicals, Inc.
Increased sympathetic noradrenergic signaling is crucially involved in fear and anxiety as defensive states. MicroRNAs regulate dynamic gene expression during synaptic plasticity and genetic variation of microRNAs modulating noradrenaline transporter gene (SLC6A2) expression may thus lead to altered central and peripheral processing of fear and anxiety. In silico prediction of microRNA regulation of SLC6A2 was confirmed by luciferase reporter assays and identified hsa-miR-579-3p as a regulating microRNA. The minor (T)-allele of rs2910931 (MAFcases = 0.431, MAFcontrols = 0.368) upstream of MIR579 was associated with panic disorder in patients (pallelic = 0.004, ncases = 506, ncontrols = 506) and with higher trait anxiety in healthy individuals (pASI = 0.029, pACQ = 0.047, n = 3112). Compared to the major (A)-allele, increased promoter activity was observed in luciferase reporter assays in vitro suggesting more effective MIR579 expression and SLC6A2 repression in vivo (p = 0.041). Healthy individuals carrying at least one (T)-allele showed a brain activation pattern suggesting increased defensive responding and sympathetic noradrenergic activation in midbrain and limbic areas during the extinction of conditioned fear. Panic disorder patients carrying two (T)-alleles showed elevated heart rates in an anxiety-provoking behavioral avoidance test (F(2, 270) = 5.47, p = 0.005). Fine-tuning of noradrenaline homeostasis by a MIR579 genetic variation modulated central and peripheral sympathetic noradrenergic activation during fear processing and anxiety. This study opens new perspectives on the role of microRNAs in the etiopathogenesis of anxiety disorders, particularly their cardiovascular symptoms and comorbidities.
Based on accumulating evidence of a role of lipid signaling in many physiological and pathophysiological processes including psychiatric diseases, the present data driven analysis was designed to gather information needed to develop a prospective biomarker, using a targeted lipidomics approach covering different lipid mediators. Using unsupervised methods of data structure detection, implemented as hierarchal clustering, emergent self-organizing maps of neuronal networks, and principal component analysis, a cluster structure was found in the input data space comprising plasma concentrations of d = 35 different lipid-markers of various classes acquired in n = 94 subjects with the clinical diagnoses depression, bipolar disorder, ADHD, dementia, or in healthy controls. The structure separated patients with dementia from the other clinical groups, indicating that dementia is associated with a distinct lipid mediator plasma concentrations pattern possibly providing a basis for a future biomarker. This hypothesis was subsequently assessed using supervised machine-learning methods, implemented as random forests or principal component analysis followed by computed ABC analysis used for feature selection, and as random forests, k-nearest neighbors, support vector machines, multilayer perceptron, and naïve Bayesian classifiers to estimate whether the selected lipid mediators provide sufficient information that the diagnosis of dementia can be established at a higher accuracy than by guessing. This succeeded using a set of d = 7 markers comprising GluCerC16:0, Cer24:0, Cer20:0, Cer16:0, Cer24:1, C16 sphinganine, and LacCerC16:0, at an accuracy of 77%. By contrast, using random lipid markers reduced the diagnostic accuracy to values of 65% or less, whereas training the algorithms with randomly permuted data was followed by complete failure to diagnose dementia, emphasizing that the selected lipid mediators were display a particular pattern in this disease possibly qualifying as biomarkers.
The cell—cell signaling gene CDH13 is associated with a wide spectrum of neuropsychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), autism, and major depression. CDH13 regulates axonal outgrowth and synapse formation, substantiating its relevance for neurodevelopmental processes. Several studies support the influence of CDH13 on personality traits, behavior, and executive functions. However, evidence for functional effects of common gene variation in the CDH13 gene in humans is sparse. Therefore, we tested for association of a functional intronic CDH13 SNP rs2199430 with ADHD in a sample of 998 adult patients and 884 healthy controls. The Big Five personality traits were assessed by the NEO-PI-R questionnaire. Assuming that altered neural correlates of working memory and cognitive response inhibition show genotype-dependent alterations, task performance and electroencephalographic event-related potentials were measured by n-back and continuous performance (Go/NoGo) tasks. The rs2199430 genotype was not associated with adult ADHD on the categorical diagnosis level. However, rs2199430 was significantly associated with agreeableness, with minor G allele homozygotes scoring lower than A allele carriers. Whereas task performance was not affected by genotype, a significant heterosis effect limited to the ADHD group was identified for the n-back task. Heterozygotes (AG) exhibited significantly higher N200 amplitudes during both the 1-back and 2-back condition in the central electrode position Cz. Consequently, the common genetic variation of CDH13 is associated with personality traits and impacts neural processing during working memory tasks. Thus, CDH13 might contribute to symptomatic core dysfunctions of social and cognitive impairment in ADHD.